Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial
Year: 2020
Type: article
Abstract: BACKGROUND: Understanding the patterns of treatment response is critical for the treatment of patients with schizophrenia; one way to achieve this is through using a longitudinal dynamic process study design. AIMS: This study aims to explore the response trajectory of antipsychotics and compare the treatment responses of seven different antipsychotics over 6 weeks in patients with schizoprenia (trial registration: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934). METHOD: Data were collected from a multicentre, randomised open-label clinical trial. Patients were evaluated with the Positive and Negative Syndrome Scale (PANSS) at baseline and follow-up at weeks 2, 4 and 6. Trajectory groups were classified by the method of k-means cluster modelling for longitudinal data. Trajectory analyses were also employed for the seven antipsychotic groups. RESULTS: The early treatment response trajectories were classified into a high-trajectory group of better responders and a low-trajectory group of worse responders. The results of trajectory analysis showed differences compared with the classification method characterised by a 50% reduction in PANSS scores at week 6. A total of 349 patients were inconsistently grouped by the two methods, with a significant difference in the composition ratio of treatment response groups using these two methods (χ2 = 43.37, P < 0.001). There was no differential contribution of high- and low trajectories to different drugs (χ2 = 12.52, P = 0.051); olanzapine and risperidone, which had a larger proportion in the >50% reduction at week 6, performed better than aripiprazole, quetiapine, ziprasidone and perphenazine. CONCLUSIONS: The trajectory analysis of treatment response to schizophrenia revealed two distinct trajectories. Comparing the treatment responses to different antipsychotics through longitudinal analysis may offer a new perspective for evaluating antipsychotics.
Source: BJPsych Open
DOI: 10.1192/bjo.2020.105
Authors: Minhan Dai, Yulu Wu, Yiguo Tang, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Wei Deng, Qi Chen, Guigang Yang, Tianlan Lu, Lifang Wang, Fude Yang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xin Ma, Lingjiang Li, Chuanyue Wang, Xiaohong Ma, Dai Zhang, Hao Yu, Liansheng Zhao, Hongyan Ren, Yingcheng Wang, Xun Hu, Guangya Zhang, Xiaodong Du, Qiang Wang, Tao Li
Institutions: West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Peking University, Peking University Sixth Hospital, Second Xiangya Hospital of Central South University, Xiangya Hospital Central South University, Capital Medical University, Beijing Anding Hospital, Beijing HuiLongGuan Hospital, Nanjing Medical University, Tianjin Medical University General Hospital, Tianjin Anding Hospital, Tianjin Medical University, Hebei Mental Health Center, Henan Psychiatric Hospital, Henan Medical University, Xijing Hospital, Air Force Medical University, Jining Medical University, Soochow University, Suzhou Guangji Hospital
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,830
Funders: Suzhou Key Medical Center, National Natural Science Foundation of China, Capital Medical University, Central South University, Sichuan University, Nanjing Medical University, Fourth Military Medical University, Soochow University, Peking University, Jining Medical University, Tianjin Medical University, Xinxiang Medical University, Xiangya Hospital, Central South University, National Key Research and Development Program of China, West China Hospital, Sichuan University
OpenAlex ID: W3093772652
